Source:http://linkedlifedata.com/resource/pubmed/id/12046390
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2002-6-5
|
pubmed:abstractText |
Heptral (Ademetionine) plays one of the main functions in the intermediate metabolism, takes part in the processes of methylation and transulfurization and aminopropylation. The use of Heptral in patients with chronic liver diseases with accompanying holystase and encephalopathy of different degree, at depressions, related to alcohol and toxic liver disorders, is pathogenically reasoned for prevention of liver encephalopathy.
|
pubmed:language |
rus
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1682-8658
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
62-4, 103
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:12046390-Chronic Disease,
pubmed-meshheading:12046390-Clinical Trials as Topic,
pubmed-meshheading:12046390-Drug-Induced Liver Injury,
pubmed-meshheading:12046390-Hepatitis, Viral, Human,
pubmed-meshheading:12046390-Humans,
pubmed-meshheading:12046390-Liver,
pubmed-meshheading:12046390-Liver Diseases,
pubmed-meshheading:12046390-S-Adenosylmethionine
|
pubmed:year |
2002
|
pubmed:articleTitle |
[Metabolism pathways and use of heptral in chronic liver diseases].
|
pubmed:affiliation |
Central Research Institute of Gastroenterology, Moscow.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|